We provide the latest news
from the world of economics and finance
(RTTNews) - Accelerate Diagnostics, Inc. (AXDX), a provider of an in vitro diagnostic platform, Tuesday announced a public offering of 4.5 million units, consisting of one common share and one warrant each.
Shares were trading down at around 18 percent in pre-market.
Underwriters of the offering will be granted an option for a 30 days period to purchase up to an additional 675,000 shares of the company's common stock and/or additional warrants at the public offering price.
William Blair & Company, L.L.C, is serving as the sole book running manager and Craig-Hallum Capital Group LLC is serving as the joint book-running manager for the offering.
In premarket activity, Accelerate Diagnostics shares are trading at $3.03 down 18.01% on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.